BMS Buys MyoKardia, Plans To Use Eliquis Experience To Grow Mavacamten
Company Sees Opportunity For A Similar Ramp-Up For The Cardiovascular Drug
Executive Summary
Paying $13.1bn for MyoKardia and its potential first-in-class HCM drug, BMS sees a blockbuster sales opportunity that it will grow gradually. MyoKardia team will be absorbed into BMS, Caforio says.
You may also be interested in...
Merck Closes In On Acceleron But BMS And Anti-Trust Regulators Could Be Obstacles
Biopharma M&A has had a quiet year so far but could heat up if rivals start vying for the biotech company.
Cardior Counts On RNA To Tackle Cardiac Disease
The German firm intends to use the proceeds from an over-subscribed round to move its micro-RNA-132 inhibitor forward into trials for heart failure and advance its pipeline.
Cytokinetics’ CK-274 Appears To Upstage BMS’s Newly Acquired Mavacamten
The REDWOOD-HCM study showed early, sustained efficacy and no serious adverse events with a drug Cytokinetics designed to be superior to mavacamten, a drug it spun out via BMS-acquired MyoKardia.